MarketCap
Facebook
X
Telegram
Navidea Biopharmaceuticals Operating Cash Flow | NAVB
Annual Operating Cash Flow Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.99 M | -10.2 M | -8.17 M | -9.35 M | 4.28 M | 59.1 M | 3.56 M | -19.1 M | -29.1 M | -35.6 M | -23.9 M | -16 M | -5.17 M | -1.48 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.1 M | -35.6 M | -7.16 M |
Quarterly Operating Cash Flow Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.28 M | 2.97 M | -1.72 M | - | -6.55 M | -4.7 M | -2.56 M | - | -7.49 M | -5.48 M | -3.06 M | - | -5.62 M | -2.99 M | -951 K | - | -6.62 M | -4.28 M | -2.17 M | - | 6.4 M | 8.29 M | -2.26 M | - | 59.7 M | 60.7 M | 67.7 M | - | 1.3 M | -1.36 M | - | - | - | -10.8 M | -4.11 M | - | -24.3 M | -17.6 M | -9.17 M | - | -24.5 M | -14.8 M | -7.4 M | - | -16.6 M | -11.5 M | -6.59 M | - | -6.3 M | -2.59 M | -1.79 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 67.7 M | -24.5 M | -433 K |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
-52.6 M | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-250 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
29.6 M | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-55.2 M | - | - | $ 401 M | USA |
 |
Rezolute
RZLT
|
-64.6 M | $ 3.94 | 1.87 % | $ 299 M | USA |
 |
Evelo Biosciences
EVLO
|
-101 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-8.07 M | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
-16.5 M | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
456 M | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
-45.4 M | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
-29 M | $ 3.63 | 3.93 % | $ 795 M | Britain |
|
Amryt Pharma plc
AMYT
|
15.5 M | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
-38.3 M | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
1.01 M | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
-98.7 M | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
-19.4 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
4.84 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
19 B | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
-76.7 M | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-76.3 M | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-9.42 M | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Cellectar Biosciences
CLRB
|
-23.1 M | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
-153 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-100 M | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Karuna Therapeutics
KRTX
|
-386 M | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
-8.19 M | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-378 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
329 M | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
142 M | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
-75 M | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
-27.2 M | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
175 M | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-32.8 M | $ 11.8 | 8.21 % | $ 932 M | USA |
|
Champions Oncology
CSBR
|
-4.47 M | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-39.6 M | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
-21.7 M | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
-17.1 M | $ 1.72 | 2.38 % | $ 13.8 M | USA |